Taysha Gene Therapies Hits New 52-Week High

Analysts Debate Whether the Stock Is Still a Buy

Apr. 16, 2026 at 8:03am

Got story updates? Submit your updates here. ›

A close-up, black-and-white image of the intricate gears and mechanisms of a complex financial machine, conveying a sense of the powerful, industrial forces driving the gene therapy sector.The soaring stock price of Taysha Gene Therapies reflects the high-stakes, high-tech machinery powering the gene therapy industry.Dallas Today

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) reached a new 52-week high during mid-day trading on Thursday, trading as high as $6.04. The stock closed at $6.00, with a trading volume of 9,830,509 shares. The company's stock has been the subject of mixed analyst ratings, with some maintaining a 'Buy' recommendation and others issuing a 'Sell' rating.

Why it matters

Taysha Gene Therapies is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. The company's stock performance and analyst coverage are closely watched by investors in the gene therapy space.

The details

Taysha Gene Therapies has seen its stock price surge in recent months, with the company's shares reaching a new 52-week high on Thursday. The stock's rise comes as the company continues to advance its pipeline of gene therapy candidates, including lead programs targeting GM2 gangliosidoses, GM1 gangliosidosis, and aromatic L-amino acid decarboxylase (AADC) deficiency. While some analysts have maintained a 'Buy' rating on the stock, citing the company's promising pipeline and growth potential, others have issued a 'Sell' recommendation, suggesting the stock may be overvalued at current levels.

  • Taysha Gene Therapies' stock reached a new 52-week high on Thursday, April 16, 2026.
  • The company's shares have been the subject of analyst coverage and rating changes in recent months.

The players

Taysha Gene Therapies, Inc.

A clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system.

Wall Street Analysts

Sell-side research analysts who cover Taysha Gene Therapies and have issued ratings and price targets on the company's stock.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee

The takeaway

Taysha Gene Therapies' stock performance and analyst coverage reflect the high level of interest and potential in the gene therapy space, as the company continues to advance its pipeline of treatments for rare neurological disorders. However, the mixed analyst ratings suggest that the stock's valuation may be a point of debate among investors.